Hemolytic-uremic syndrome

	Hemolytic-uremic syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hemolytic-uremic syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hemolytic-uremic syndrome On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hemolytic-uremic syndrome All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hemolytic-uremic syndrome
CDC on Hemolytic-uremic syndrome
Hemolytic-uremic syndrome in the news
Blogs on Hemolytic-uremic syndrome
Directions to Hospitals Treating Hemolytic-uremic syndrome
Risk calculators and risk factors for Hemolytic-uremic syndrome

	Hemolytic-uremic syndrome;
ICD-10	D59.3
ICD-9	283.11
OMIM	235400
DiseasesDB	13052
MedlinePlus	000510
MeSH	D006463

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Synonyms and keywords:

endothelial cytotoxicity in the hemolytic uremic syndrome after infection with shiga toxin–producing Escherichia coli or other microorganisms. Thrombotic microangiopathy can also occur in patients with pneumococcal sepsis and less commonly other infections in which microbial neuraminidases expose the Thomsen-Friedenreich antigen on endothelial and red cells, subjecting the cells to attack by preexisting antibodies against the antigen